Zacks Investment Research on MSN

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

Merck’s MRK shares have risen almost 13% in the past week as Pfizer’s PFE landmark deal with the Trump administration to ...
BioSpace

September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats

The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
BioPharma Dive

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.
The New York Times

A New Shot for Cancer Is Convenient, but Poised to Keep Prices High

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
Seeking Alpha

IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study

IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer ...